The US FDA has approved Zycubo (copper histidinate), a novel subcutaneous injectable therapy developed by Sentynl Therapeutics, for treating Menkes disease in pediatric patients. This marks the first approved treatment for the rare X-linked genetic disorder characterized by severe copper transport deficiency. The drug, manufactured by Zydus Lifesciences Limited, is specifically designed to address the underlying metabolic defect caused by mutations in the ATP7A gene.

Clinical development of Zycubo was supported by two open-label, single-arm trials demonstrating remarkable improvements in patient outcomes. The pivotal studies showed a nearly 80% reduction in mortality risk, with median overall survival extending to 177.1 months for patients receiving early treatment, compared to just 17.6 months in an untreated control cohort. These results represent a transformative advancement for a condition where most untreated patients historically do not survive beyond three years of age.

Menkes disease disrupts copper transport at a fundamental cellular level, preventing patients from properly absorbing and distributing this critical micronutrient. The ATP7A gene mutation impairs copper absorption from the digestive system and blocks transport across the blood-brain barrier, leading to severe neurological complications. By delivering elemental copper through a histidinate formulation, Zycubo bypasses the genetic transport dysfunction, potentially restoring critical enzymatic processes essential for neurological development.

Implications

Until now, Menkes disease represented a devastating diagnosis with no approved therapeutic interventions. The condition’s genetic nature means affected children experience progressive neurological deterioration, characterized by developmental delays, seizures, and connective tissue abnormalities. The minimum estimated birth prevalence is approximately 1 in 34,810 live male births, making it an ultra-rare disorder that has long been overlooked by traditional drug development pathways.

The competitive landscape for Menkes disease remains essentially uncontested. Zycubo’s approval represents a singular breakthrough, with no other clinical-stage assets currently pursuing similar copper replacement strategies for this specific genetic disorder. The drug’s breakthrough therapy and orphan drug designations underscore its potential to address a critical unmet medical need.

The approval comes with important safety considerations. Patients will require careful monitoring for potential copper accumulation and associated risks of kidney, liver, and hematological complications. The most common adverse reactions include pneumonia, viral infections, respiratory complications, and seizures—reflecting the complex medical challenges inherent in treating this severe genetic condition.